Account
New to ADSS? Open an
account now to get started.
Already have an account?
Add funds to your ADSS account
Account
New to ADSS? Open an
account now to get started.
Add funds to your ADSS account
The healthcare sector includes all companies involved in providing medical services, manufacturing medical equipment, developing pharmaceuticals and biotechnology products, and managing healthcare facilities. They discover and sell products that cure illness or prevent disease or offer healthcare services to clients.
With ADSS, investors can access and invest in healthcare stocks with zero commission.
The healthcare sector includes pharmaceutical companies, biotechnology firms, medical device manufacturers, health insurers, hospital operators, and healthcare service providers. The best-known subsector is the pharmaceutical industry.
Healthcare stocks have the following important characteristics: the services and products they provide are essential, the market they operate in is highly regulated, and typically firms operate with high margins. Investing in healthcare stocks provides exposure to a sector with long-term growth potential driven by demographic trends, technological innovation, and increasing global healthcare spending.
Healthcare demand remains relatively stable across economic cycles, providing defensive characteristics similar to consumer staples, but with greater growth potential and in the pharmaceuticals subsector, the unique dynamic of drug discovery and marketing. Pharmaceutical and biotechnology companies generate revenue through developing and commercialising new drugs, which can create significant returns when successful but also carries substantial research and development risks.
Healthcare companies operate in a highly regulated environment, with government policies on drug pricing, generic medicines, insurance coverage, and healthcare delivery significantly impacting profitability. National authorities may withdraw drugs from the market, change the rules surrounding prescriptions, and even mandate insurance coverage for citizens.
This creates a strong political and regulatory influence on the sector that can be hard to predict, with both potential upside and downside for healthcare stocks. Strict regulations combined with high profit margins give healthcare stocks some characteristics in common with the financial sector. The highly international nature of many healthcare companies means they operate in multiple different regulatory regimes, increasing the compliance and legal complexity of delivering healthcare services.
Pricing from TradingView is indicative and does not represent ADSS pricing.
Healthcare stocks are heavily influenced by regulatory change and policy decisions, with changes in healthcare legislation market-moving events. Major regulatory shifts, such as the implementation of pricing transparency requirements, drug approval pathway reforms, and insurance market regulations, directly impact revenue across the sector.
Pharmaceutical companies particularly face scrutiny over drug approval timelines, with regulatory bodies like the Food and Drug Administration (FDA) in the US and the European Medicines Authority (EMA) continually evolving their requirements for clinical trial design and safety monitoring. Once developed and marketed, drugs are sometimes withdrawn, given box warnings, or have prescribing restrictions introduced, all of which can negatively impact the sales of popular medicines.
Drug pricing reform remains a persistent theme impacting pharmaceutical and biotechnology stocks, with governments worldwide using different mechanisms to control healthcare expenditure. When developing new drugs, pharmaceutical companies benefit from a 20-year patent during which only the official brand can be sold, which is typically far more expensive than unbranded or generic equivalents.
During the 20-year period, high margins allow pharmaceuticals companies to recuperate the cost of development of the drug itself and of the many drug candidates which do not make it through development. Increasingly, governments are under pressure to put additional restrictions on the pricing of branded drugs during the patent period. The proposal or success of legislation limiting drug prices is a potential risk for pharma stock valuation.
Other significant trends impacting healthcare stocks include consolidation, with hospital groups merging to gain negotiating leverage against insurers; biosimilar (slightly changed versions of biological medicines) adoption as biological medicine patents expire; and a growing focus preventative care models to reduce long-term healthcare costs.
Healthcare companies are responding to these challenges by diversifying geographic exposure, pursuing indication expansions for existing medications (using an existing drug to treat new conditions), and developing specialty therapies for rare diseases where pricing pressure is less intense. Despite the complex regulatory environment, healthcare remains an essential sector with demographic tailwinds supporting long-term demand.
Fund
Fund using Mastercard, VISA, UAEPGS (for UAE bank accounts holders only)
Invest
Invest in healthcare stocks through the ADSS platform
The healthcare industry faces major changes from several factors: an ageing global population that needs more care, improvements in pharmaceutical manufacturing methods, and new regulations affecting prices. Medical innovation continues in preventative medicine and digital health, while mergers between hospital groups and insurance providers are changing how companies compete. The pharmaceutical industry must navigate patent expirations while seeking growth in new markets, making healthcare stocks particularly sensitive to government decisions and regulations in different countries.
Clinical trial phases have direct effects on pharma stocks through their step-by-step approach to drug development. Phase I tests safety in healthy people, Phase II examines if the drug works in a small patient group, Phase III confirms benefits in larger populations, and Phase IV tracks long-term effects after approval. Stocks typically rise when a drug passes each phase, with Phase III results and final approvals causing the biggest price increases. However, failed trials or regulatory problems can sharply reduce share values, especially for smaller biotech companies with few products in development, making knowledge of clinical trial phases essential for investors.
Biosimilars are approved versions of existing biologic medicines that become available after the original product’s patent ends. Unlike standard generic drugs, biosimilars aren’t exact copies but highly similar versions of complex biologic treatments that work in comparable ways. They create price competition, which can lower healthcare costs and allow more patients to access important treatments. For investors in the pharmaceutical industry, biosimilars create opportunities for companies making these alternatives but challenges for original drug makers who lose revenue after patents expire, with approval processes and doctor acceptance varying widely across global markets.
Within healthcare services, several areas show particularly good investment potential: telemedicine services that use technology to improve access to care; specialised outpatient clinics offering less expensive alternatives to hospitals; mental health services meeting growing demand; and home healthcare companies benefiting from ageing populations who prefer treatment at home. Healthcare information technology firms that create solutions for better administration and clinical decision-making are also growing substantially. Investors should consider exposure to regulations, payment systems, and competitive pressures when evaluating individual healthcare services stocks, as performance often varies significantly based on location and specific services offered.
ADSS
8th floor, CI Tower
Corniche Road
PO Box 93894
Abu Dhabi
United Arab Emirates
Trading Services
ts@adss.com
+971 2 657 2414
Investing in CFDs involves a high degree of risk that you will lose your money due to the use of leverage, particularly in fast moving markets, where a relatively small movement in the price can lead to a proportionately larger movement in the value of your investment. This can result in loses that exceed the funds in your account. You should consider whether you understand how CFDs work and you should seek independent advice if necessary.
ADS Securities L.L.C – S.P.C (“ADSS”), a limited liability company – sole proprietorship company incorporated under United Arab Emirates law. Registered under Commercial License No.1190047. ADS Securities L.L.C S.P.C is regulated and authorised in the UAE by the Capital Market Authority (CMA) under Category 1 License No.305027 (Trading Broker, Trading and Clearing Broker, Trading Broker in the International Markets, Trading Broker of OTC Derivatives and Currencies in the Spot Market, Financial Products Dealer) and Category 5 License No.20200000217 (Introduction). Registered Office: 8th Floor, CI Tower, Corniche Road, P.O. Box 93894, Abu Dhabi, United Arab Emirates.
The information presented is not directed at residents of any particular country outside the United Arab Emirates and is not intended for distribution to, or use by, any person in any country where the distribution or use is contrary to local law or regulation.
ADSS is an execution only service provider and does not provide advice. ADSS may publish general market commentary from time to time. Where it does, the material published does not constitute advice, or a solicitation, or a recommendation to a transaction in any financial instrument. ADSS accepts no responsibility for any use of the content presented and any consequences of that use. No representation or warranty is given as to the completeness of this information. Anyone acting on the information provided does so at their own risk.
